← Back to contracts

Center for Research on Complex Generics (U18) Clinical Trials Optional

US · MD Food and Drug Administration (HHS-FDA) grant unknown #FOR-FD-25-004

Summary

The Food and Drug Administration (FDA) is forecasting a funding opportunity for a Center for Research on Complex Generics under the U18 cooperative agreement mechanism. The program supports research focused on complex generic drug products, with clinical trials listed as optional. This is a forecasted opportunity, meaning final details such as award amounts and deadlines have not yet been published. The grant is administered through HHS-FDA and posted on Grants.gov.

What they want

Establish and operate a Center for Research on Complex Generics under the NIH/FDA U18 cooperative agreement mechanism. The center is expected to conduct research on complex generic pharmaceuticals. Clinical trials are permitted but not required. Full programmatic scope, deliverables, and eligibility requirements are pending publication of the complete solicitation.
Technical requirements
  • Cooperative agreement mechanism U18 applies
  • Clinical trials are optional (not required) under this opportunity
  • Research must address complex generic drug products

Risks & flags

  • Opportunity is in 'forecasted' status — no full solicitation details, eligibility criteria, or funding levels have been published yet, limiting competitive preparation time once the full notice drops.

Market context

inferred from NAICS
R&D in Physical, Engineering, Life Sciences (except Nanotech & Biotech)
NAICS 541715
US market size
$95B
Typical award
$100K – $50M+
Typical buyers
DoDNSFNIHNASADOE
Commonly required
DCAA-compliant accountingITARCMMC L2
Center for Research on Complex Generics (U…
$unknown
Onboard ↗